Description
D3s-001 is an experimental medication currently being studied in clinical trials for certain types of advanced solid tumors, including colorectal cancer. It is specifically being investigated in patients whose tumors have a KRAS p.G12C mutation. This mutation is a change in the KRAS gene, which can sometimes cause cancer cells to grow and spread. D3s-001 is taken orally (by mouth) once a day in cycles. The goal of the ongoing Phase 1 trial is to determine the safest dose of D3s-001 and to see if it has any effect on the cancer. It is also being tested in combination with other cancer drugs like carboplatin, cetuximab, cisplatin, pembrolizumab, and pemetrexed.
Mechanism of Action
D3s-001 is being developed as a potential treatment for cancers with a specific KRAS p.G12C mutation. The exact way D3s-001 works (its specific molecular target) is still being investigated in clinical trials. However, it is designed to target the effects of the KRAS p.G12C mutation in cancer cells, potentially interfering with their growth or survival.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.